Gregory Locke

机构：Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Belgium)

发表论文 39 篇 · 总被引 590 次 · h-index 15

代表论文

• Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor (2021 · Journal for ImmunoTherapy of Cancer · 被引 77)
• Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1 (2021 · ACS Medicinal Chemistry Letters · 被引 58)
• Discovery of Non-Nucleotide Small-Molecule STING Agonists via Chemotype Hybridization (2022 · Journal of Medicinal Chemistry · 被引 34)
• DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity (2023 · Science Translational Medicine · 被引 29)
• Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase (2020 · Bioorganic & Medicinal Chemistry · 被引 26)
• Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO) (2021 · Bioorganic & Medicinal Chemistry Letters · 被引 18)